New hepatitis b drug enters first human tests
NCT ID NCT07024641
First seen Jun 24, 2026 · Last updated Jul 17, 2026 · Updated 2 times
Summary
This early-stage trial is testing an experimental drug called GIGA-2339 in 48 adults with chronic hepatitis B. The main goal is to check if the drug is safe and how the body processes it. Participants will receive either GIGA-2339 or a placebo by IV infusion, and researchers will monitor for side effects and measure drug levels in the blood.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- GIGA-2339 (an experimental drug given by IV infusion)
- What this could lead to
- If successful, this could lead to a new treatment option for chronic hepatitis B, potentially helping control the virus long-term.
- What could go wrong
- This is a very early Phase 1 trial with only 48 people, focused on safety and dosing. It is too soon to know if GIGA-2339 will effectively treat hepatitis B, and side effects are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B VIRUS INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Grifols Investigate Site
RECRUITINGConcord, New South Wales, 2139, Australia
-
Grifols Investigative Site
RECRUITINGPeachtree Corners, Georgia, 30071, United States
-
Grifols Investigative Site
RECRUITINGIowa City, Iowa, 52242, United States
-
Grifols Investigative Site
RECRUITINGLenexa, Kansas, 66219, United States
-
Grifols Investigative site
RECRUITINGChandler, Arizona, 85225, United States
-
Grifols Investigative site
RECRUITINGHuntington Beach, California, 92647, United States
-
Grifols Investigative site
RECRUITINGLake Forest, California, 92630, United States
-
Grifols Investigative site
RECRUITINGLong Beach, California, 90805, United States
-
Grifols Investigative site
SUSPENDEDOakland, California, 94605, United States
-
Grifols Investigative site
RECRUITINGBaltimore, Maryland, 21287, United States
-
Grifols Investigative site
RECRUITINGSan Antonio, Texas, 78215, United States
-
Grifols Investigative site
RECRUITINGWebster, Texas, 77598, United States
-
Grifols Investigative site
RECRUITINGRichmond, Virginia, 23284, United States
-
Grifols Investigative site
RECRUITINGFortitude Valley, Queensland, 4006, Australia
-
Grifols Investigative site
RECRUITINGHong Kong, Hong Kong Island, Hong Kong
-
Grifols Investigative site
RECRUITINGShatin, New Territories, Hong Kong
-
Grifols Investigative site
RECRUITINGSeogu, Busan, South Korea
-
Grifols Investigative site
RECRUITINGSongpa-dong, Seoul, South Korea
-
Grifols Investigative site
RECRUITINGSanmin, Kaohsiung, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New blood test may sharpen diagnosis of autoimmune liver disease
- Two-Drug combo aims to cure chronic hepatitis b
- New injection aims to tame chronic hepatitis b
- Zambia study tracks hepatitis b outcomes in hundreds of patients
- New drug cocktail shows promise for liver cancer in hepatitis b patients
- New shot aims to tame hepatitis b virus